Ivabradine, coronary artery disease, and heart failure: beyond rhythm control

References

• Giannoglou GD Chatzizisis YS Zamlis C Parcharidis GE Mikhailidis DP Louridas GE Elevated heart rate and atherosclerosis. An overview of the pathogenetic mechanisms Int J Cardiol 2008 126 3 302 312 18068835
   PubMed Web of Science ®Google Scholar
• Scicchitano P Carbonara S Ricci G HCN channels and heart rate Molecules 2012 17 4 4225 4235 22481543
   PubMed Web of Science ®Google Scholar
• Colin P Ghaleh B Monnet X Contributions of heart rate and contractility to myocardial oxygen balance during exercise Am J Physiol Heart Circ Physiol 2003 284 2 H676 H682 12399255
   PubMed Web of Science ®Google Scholar
• Parakh N Bhargara B Rate control with Ivabradine Am J Cardiovasc Drugs 2011 11 1 1 12 21090826
   PubMed Web of Science ®Google Scholar
• Thollon C Villaine JP If inhibition in cardiovascular diseases Adv Pharmacol 2010 59 53 92 20933199
   PubMedGoogle Scholar
• Tardif JC Clinical results of If current inhibitor by ivabradine Drugs 2007 67 Suppl 2 S35 S41
   Web of Science ®Google Scholar
• Riccioni G Vitulano N D’Orazio N Ivabradine: beyond heart rate control Adv Ther 2009 26 1 12 24 19165437
   PubMed Web of Science ®Google Scholar
• Menown IB Ivabradine: a new strategy for management of stable angina Br J Hosp Med 2007 68 6 21 25
   Web of Science ®Google Scholar
• Thollon C Bidouard JP Cambarrat C Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+) -S 16257 Eur J Pharmacol 1997 339 1 43 51 9450615
   PubMed Web of Science ®Google Scholar
• Ragueneau I Laveille C Jochemsen R Resplandy G Funck-Brentano C Jaillon P Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers Clin Pharmacol Ther 1998 64 2 192 203 9728900
   PubMed Web of Science ®Google Scholar
• Thollon C Cambarrat C Vian J Prost JF Peglion JL Vilaine JP Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49 Br J Pharmacol 1994 112 1 37 42 8032660
   PubMed Web of Science ®Google Scholar
• Bois P Bescond J Renaudon B Lenfant J Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells Br J Pharmacol 1996 118 4 1051 1057 8799581
   PubMed Web of Science ®Google Scholar
• Bucchi A Baruscotti M DiFrancesco D Current-dependent block of rabbit sino-atrial node If channels by ivabradine J Gen Physiol 2002 120 1 1 13 12084770
   PubMed Web of Science ®Google Scholar
• Savelieva I Camm AJ If inhibition with ivabradine: electrophysiological effects and safety Drug Saf 2008 31 2 95 107 18217787
   PubMed Web of Science ®Google Scholar
• Rosa GM Ferrero S Ghione P Valbusa A Brunelli C An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure Expert Opin Drug Metab Toxicol 2014 10 2 279 291 24377458
   PubMed Web of Science ®Google Scholar
• DiFrancesco D Camm JA Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease Drugs 2004 64 16 1757 1765 15301560
   PubMed Web of Science ®Google Scholar
• Borer JS Fox K Jaillon P Lerebours G Ivabradine Investigators Group Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial Circulation 2003 107 6 817 823 12591750
   PubMed Web of Science ®Google Scholar
• Tardif JC Ford I Tendera M Bourassa MG Fox K INITIATIVE Investigators Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina Eur Heart J 2005 26 23 2529 2536 16214830
   PubMed Web of Science ®Google Scholar
• Camm AJ How does pure heart rate lowering impact on cardiac tolerability? Eur Heart J Suppl 2006 8 Suppl D D9 D15
   Web of Science ®Google Scholar
• Murat SN Orcan S Akdemir R Dogan M Kara E Balci M Arrhythmic effects of ivabradine in patients with coronary artery disease Clin Invest Med 2009 32 5 E322 E326 19796572
   PubMed Web of Science ®Google Scholar
• Scott AE Kruszewski K Leslie SJ Sinus node If channel inhibition – a new therapeutic approach to heart rate lowering Curr Drug Therapy 2009 4 1 12 18
   Google Scholar
• Swedberg K Komajda M Bohm M SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 2010 376 9744 875 885 20801500
   PubMed Web of Science ®Google Scholar
• Custodis F Baumhäkel M Schlimmer N Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice Circulation 2008 117 18 2377 2387 18443241
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A Blanco-Palacios G Abreu-Gonzales P Increased heart rate and atherosclerosis: potential implications of ivabradine therapy World J Cardiol 2011 3 4 101 104 21526046
   PubMedGoogle Scholar
• Fox K Ford I Steg PG Tendera M Ferrari R BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 2008 372 9641 807 816 18757088
   PubMed Web of Science ®Google Scholar
• Fox K Ford I Steg PG Tendera M Robertson M Ferrari R BEAUTIFUL investigators Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial Lancet 2008 372 9641 817 821 18757091
   PubMed Web of Science ®Google Scholar
• Bruguera Cortada J Varela A Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice Am J Cardiovasc Drugs 2009 9 Suppl 9 12 20000882
   PubMed Web of Science ®Google Scholar
• Fox K Ford I Steg PG Tendera M Robertson M Ferrari R BEAUTIFUL Investigators Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial Eur Heart J 2009 30 19 2337 2345 19720635
   PubMed Web of Science ®Google Scholar
• Tendera M Talajic M Robertson M BEAUTIFUL Investigators Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy) Am J Cardiol 2011 107 6 805 811 21247517
   PubMed Web of Science ®Google Scholar
• Ferrari R A step further with ivabradine: SIGNIfY (Study assessInG the morbidity–mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease) Eur Heart J 2009 11 Suppl D 19 27
   Web of Science ®Google Scholar
• Lucats L Ghaleh B Colin P Monnet X Bizé A Berdeaux A Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening Br J Pharmacol 2007 150 3 335 341 17179940
   PubMed Web of Science ®Google Scholar
• Tardif JC Ponikowski P Kahan T ASSOCIATE Investigators Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study Int J Cardiol 2013 168 2 789 794 23138014
   PubMed Web of Science ®Google Scholar
• Köster R Kaehler J Meinertz T REDUCTION Study Group Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study Am Heart J 2009 158 4 51 57
   Web of Science ®Google Scholar
• Heusch G Skyschally A Gres P van Caster P Schilawa D Schulz R Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur Heart J 2008 29 18 2265 2275 18621770
   PubMed Web of Science ®Google Scholar
• Beere PA Glagov S Zarins CK Retarding effect of lowered heart rate on coronary atherosclerosis Science 1984 226 4671 180 182 6484569
   PubMed Web of Science ®Google Scholar
• Prosi M Perktold K Ding Z Friedman MH Influence of curvature dynamics on pulsatile coronary artery flow in a realistic bifurcation model J Biomech 2004 37 11 1767 1775 15388320
   PubMed Web of Science ®Google Scholar
• Drouin A Gendron ME Thorin E Gillis MA Mahlberg-Gaudin F Tardif JC Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice Br J Pharmacol 2008 154 4 749 757 18414390
   PubMed Web of Science ®Google Scholar
• Rogowski O Shapira I Shirom A Melamed S Toker S Berliner S Heart rate and microinflammation in men: a relevant atherothrombotic link Heart 2007 93 8 940 944 17237129
   PubMed Web of Science ®Google Scholar
• Monnet X Ghaleh B Colin P de Curzon OP Giudicelli JF Berdeaux A Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning J Pharmacol Exp Ther 2001 299 3 1133 1139 11714904
   PubMed Web of Science ®Google Scholar
• Monnet X Colin P Ghaleh B Hittinger L Giudicelli JF Berdeaux A Heart rate reduction during exercise-induced myocardial ischaemia and stunning Eur Heart J 2004 25 7 579 586 15120055
   PubMed Web of Science ®Google Scholar
• Lucats L Ghaleh B Monnet X Colin P Bizé A Berdeaux A Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning Eur Heart J 2007 28 7 872 879 17376788
   PubMed Web of Science ®Google Scholar
• Pagidipati NJ Gaziano TA Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement Circulation 2013 127 6 749 756 23401116
   PubMed Web of Science ®Google Scholar
• Heusch G Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents Br J Pharmacol 2008 153 8 1589 1601 18223669
   PubMed Web of Science ®Google Scholar
• Custodis F Schirmer SH Baumhäkel M Heusch G Böhm M Laufs U Vascular pathophysiology in response to increased heart rate J Am Coll Cardiol 2010 56 24 1973 1983 21126638
   PubMed Web of Science ®Google Scholar
• Skalidis EI Hamilos MI Chlouverakis G Zacharis EA Vardas PE Ivabradine improves coronary flow reserve in patients with stable coronary artery disease Atherosclerosis 2011 215 1 160 165 21183181
   PubMed Web of Science ®Google Scholar
• Zuanetti G Mantini L Hernández-Bernal F Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study Eur Heart J 1998 19 Suppl F F19 F26 9651731
   PubMed Web of Science ®Google Scholar
• Riccioni G Ivabradine: an intelligent drug for the treatment of ischemic heart disease Molecules 2012 17 11 13592 13604 23159921
   PubMed Web of Science ®Google Scholar
• Riccioni G Ivabradine: the hope for a good treatment of ischemic heart disease Curr Med Chem 2013 20 4 1817 1823 23394554
   PubMed Web of Science ®Google Scholar
• Mulder P Barbier S Chagraoui A Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure Circulation 2004 109 13 1674 1679 14981003
   PubMed Web of Science ®Google Scholar
• Fasullo S Cannizzaro S Maringhini G Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings J Card Fail 2009 15 10 856 863 19944362
   PubMedGoogle Scholar
• Riccioni G Ivabradine: from molecular basis to clinical effectiveness Adv Ther 2010 27 3 160 167 20419486
   PubMed Web of Science ®Google Scholar
• Rozanski A Qureshi E Bauman M Reed G Pillar G Diamond GA Peripheral Arterial Responses to treadmill exercise among healthy subjects and atherosclerotic patients Circulation 2001 103 2084 2089 11319199
   PubMed Web of Science ®Google Scholar
• Böhm M Reil JC Perspectives of I(f) inhibition by ivabradine in cardiology Drugs 2007 67 Suppl 2 43 49 17999563
   PubMed Web of Science ®Google Scholar
• Simon L Ghaleh B Puybasset L Giudicelli JF Berdeaux A Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs J Pharmacol Exp Ther 1995 275 2 659 666 7473152
   PubMed Web of Science ®Google Scholar
• Linka AZ Sklenar J Wei K Jayaweera AR Skyba DM Kaul S Assessment of transmural distribution of myocardial perfusion with contrast echocardiography Circulation 1998 98 18 1912 1920 9799213
   PubMed Web of Science ®Google Scholar
• Van Camp G Ay T Pasquet A Quantification of myocardial blood flow and assessment of its transmural distribution with real-time power modulation myocardial contrast echocardiography J Am Soc Echocardiogr 2003 16 3 263 270 12618735
   PubMed Web of Science ®Google Scholar
• Schulz R Heusch G The relationship between regional blood flow and contractile function in normal, ischemic, and reperfused myocardium Basic Res Cardiol 1998 93 6 455 462 9879451
   PubMed Web of Science ®Google Scholar
• Decking UK Schrader J Spatial heterogeneity of myocardial perfusion and metabolism Basic Res Cardiol 1998 93 6 439 445 9879449
   PubMed Web of Science ®Google Scholar
• Hsu LY Groves DW Aletras AH Kellman P Arai AE A fully quantitative pixel-wise measurement of myocardial blood flow by contrast-enhanced first-pass CMR perfusion imaging: microsphere validation in dogs and feasibility study in humans JACC Cardiovasc Imaging 2012 5 2 154 166 22340821
   PubMed Web of Science ®Google Scholar
• Fox K Garcia MA Ardissino D Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology ESC Committee for Practice Guidelines (CPG) Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology Eur Heart J 2006 27 11 1341 1381 16735367
   PubMed Web of Science ®Google Scholar
• Canet E Lerebours G Vilaine JP Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine Ann N Y Acad Sci 2011 1222 90 99 21434947
   PubMed Web of Science ®Google Scholar
• Fox K Ford I Steg PG Tardif JC Tendera M Ferrari R Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure Am Heart J 2013 166 4 654 661.e6 24093844
   PubMed Web of Science ®Google Scholar
• Tardif JC Ponikowski P Kahan T ASSOCIATE Study Investigators Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial Eur Heart J 2009 30 5 540 548 19136486
   PubMed Web of Science ®Google Scholar
• Amosova E Andrejev E Zaderey I Rudenko U Ceconi C Ferrari R Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina Cardiovasc Drugs Ther 2011 25 6 531 537 21830063
   PubMed Web of Science ®Google Scholar
• Ruzyllo W Tendera M Ford I Fox KM Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial Drugs 2007 67 3 393 405 17335297
   PubMed Web of Science ®Google Scholar
• Marquis-Gravel G Tardif JC Ivabradine: the evidence of its therapeutic impact in angina Core Evid 2008 3 1 1 12 20694080
   PubMedGoogle Scholar
• Vaillant F Timour Q Descotes J Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study J Cardiovasc Pharmacol 2008 52 6 548 554 19034029
   PubMed Web of Science ®Google Scholar
• Vaillant F Dehina L Mazzadi A Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: role of myocyte structure and myocardial perfusion Resuscitation 2011 82 8 1092 1019 21561702
   PubMed Web of Science ®Google Scholar
• Vaillant F Dehina L Dizerens N Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status Resuscitation 2013 84 3 384 390 22940600
   PubMed Web of Science ®Google Scholar
• Heusch G A BEAUTIFUL lesson – ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J 2009 30 19 2300 2301 19720636
   PubMed Web of Science ®Google Scholar
• Dickstein K Cohen-Solal A Filippatos G ESC Committee for Practice Guidelines (CPG) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 2008 10 10 933 989 18826876
   PubMed Web of Science ®Google Scholar
• Heusch G Heart rate and heart failure. Not a simple relationship Circ J 2011 75 2 229 236 21041970
   PubMed Web of Science ®Google Scholar
• McAlister FA Wiebe N Ezekowitz JA Leung AA Armstrong PW Meta-analysis: beta-blockers dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 2009 150 784 794 19487713
   PubMed Web of Science ®Google Scholar
• Doughty RN Whalley GA Walsh HA Gamble GD López-Sendón J Sharpe N CAPRICORN Echo Substudy Investigators Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy Circulation 2004 109 2 201 206 14707020
   PubMed Web of Science ®Google Scholar
• Ferrari R Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study Arch Intern Med 2006 166 6 59 66
   Google Scholar
• Remme WJ Riegger G Hildebrandt P The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN) 2004 18 1 57 66
   Google Scholar
• Flannery G Gehrig-Mills R Billah B Krum H Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers Am J Cardiol 2008 101 6 865 869 18328855
   PubMed Web of Science ®Google Scholar
• Ekman I Chassany O Komajda M Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study Eur Heart J 2011 32 19 2395 2404 21875859
   PubMed Web of Science ®Google Scholar
• Teerlink JR Ivabradine in heart failure – no paradigm SHIFT … yet Lancet 2010 376 9744 847 849 20801501
   PubMed Web of Science ®Google Scholar
• Fang Y Debunne M Vercauteren M Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia J Cardiovasc Pharmacol 2012 59 3 260 267 22075752
   PubMed Web of Science ®Google Scholar
• Reil JC Reil GH Böhm M Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction Trends Cardiovasc Med 2009 19 5 152 157 20005474
   PubMed Web of Science ®Google Scholar
• Setakis E Kassianos G Cockle S Adverse events and subsequent changes in beta-blocker treatment in coronary heart disease patients in UK primary care Eur Heart J 2009 30 974 Suppl 1 Abstract P5476
   Google Scholar
• Couvreur N Tissier R Pons S Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression Eur Heart J 2010 31 12 1529 1537 20028694
   PubMed Web of Science ®Google Scholar
• Ceconi C Freedman SB Tardif JC BEAUTIFUL Echo-BNP Investigators Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL Int J Cardiol 2011 14 408 414 21112101
   PubMed Web of Science ®Google Scholar
• Troughton RW Richards AM Yandle TG Frampton CM Nicholls MG The effects of medications on circulating levels of cardiac natriuretic peptides Ann Med 2007 39 4 242 260 17558597
   PubMed Web of Science ®Google Scholar
• Difrancesco D Funny channel gene mutations associated with arrhythmias J Physiol 2013 591 17 4117 4124 23507880
   PubMed Web of Science ®Google Scholar
• Benezet-Mazuecos J Rubio JM Farré J Quiñones MÁ Sanchez-Borque P Macía E Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients Pacing Clin Electrophysiol 2013 36 7 830 836 23510001
   PubMed Web of Science ®Google Scholar
• Kuwabara Y Kuwahara K Takano M Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts J Am Heart Assoc 2013 2 3 e000150 23709563
   PubMed Web of Science ®Google Scholar
• Suenari K Cheng CC Chen YC Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis J Cardiovasc Electrophysiol 2012 23 2 200 206 21914029
   PubMed Web of Science ®Google Scholar
• Plotnikov AN Bucchi A Shlapakova I HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I(f) blockade Heart Rhythm 2008 5 2 282 288 18242555
   PubMed Web of Science ®Google Scholar
• Tamura A Ogura T Uemura H Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current J Pharmacol Sci 2009 110 2 150 159 19498275
   PubMed Web of Science ®Google Scholar
• Fan X Chen Y Wu P Novel electropharmacological activity of amiodarone on human HCN channels heterologously expressed in the Xenopus oocytes Eur J Pharmacol 2011 669 1–3 15 23 21839071
   PubMed Web of Science ®Google Scholar